| |
A critical area to consider in selecting a CDMO is their ability to successfully complete technology transfers. Recognizing what it takes to complete this process effectively and efficiently is crucial to selecting the best partner for your project and product needs. This white paper delivers an analysis of critical success factors for effective technology transfer. 
|
|
Today’s Big NewsDec 5, 2023 |
| By Fraiser Kansteiner During an enterprise business review Tuesday, J&J laid out a range of expectations across the 2025 to 2030 timeframe. Chief among those, J&J says it will boast more than 10 drugs with peak sales potential of at least $5 billion, plus another 15-plus products with sales potential of at least $1 billion. |
|
|
|
By Angus Liu Eli Lilly has pushed back the deadline of its tender offer for radiotherapy company Point Biopharma’s shares for a second time. According to two senior executives, Lilly’s current predicament is caused not by any internal factors but by Point’s rival, Novartis. |
By Gabrielle Masson Days away from an FDA decision on a sickle cell gene therapy, CRISPR Therapeutics is ditching its “first-generation” allogeneic CAR-T candidates and expanding into autoimmune disease. |
By Ben Adams Swiss major Novartis is leaning on its roots as it launches a new look for the company after this year’s Sandoz spinoff and pipeline refocus. |
|
Thursday, December 13, 2023 | 11am ET / 8am PT In this webinar discover how CDMOs drive efficiency, ensure quality, and enable scalability in biologics production and stay ahead in the dynamic world of biologics with a focus on the transformative CDMO impact. Reigster now. 
|
|
By Andrea Park After wrapping up bankruptcy proceedings over the summer and, according to the company, emerging with all of its material customer contracts and tech development programs still in place, Rockley is ready to return to the process of finding buyers for its wrist-based biosensor. |
By Andrea Park For the first time, according to researchers, an implanted device has successfully demonstrated long-term improvements following a traumatic brain injury. |
By Angus Liu Despite what was presented as a “landmark” deal between the pharmaceutical companies and the government, the U.K.’s pharma association has not stopped pressuring the government for more industry-friendly spending policies. |
By Max Bayer Johnson & Johnson's neuroscience pipeline is taking center stage, now one of three therapeutic focus areas mentioned in the company's business review. Three neuroscience drugs are expected to rake in $1-5 billion in revenue by 2030. |
By Nick Paul Taylor Roche’s pitch to reset the standard of care in a breast cancer population has cleared a late-phase hurdle. The drugmaker’s attempt to improve on Novartis’ Piqray and deliver a first-line PI3K inhibitor has yielded a improved progression-free survival (PFS) in phase 3, teeing up talks with regulatory authorities. |
By Nick Paul Taylor Salix Pharmaceuticals is putting a new date in the disease awareness calendar. Working with two nonprofits, the drugmaker has declared Dec. 5 Opioid-Induced Constipation (OIC) Awareness Day to try to tackle the stigma and silence surrounding this condition. |
By Nick Paul Taylor Chiesi is working with the BBC to show off its climate-conscious credentials, partnering with the British broadcaster on a web series episode about redesigning inhalers to reduce their environmental impact. |
By Kevin Dunleavy Travere Therapeutics will reduce its workforce by 20%, with the job cuts focused on “non-field-based employees,” the company said on Tuesday. The layoffs are part of a shake-up of the San Diego-based company as it focuses on its launch of kidney drug Filspari and develops pegtibatinase as a potential treatment for the metabolic disorder homocystinuria (HCU). |
By Conor Hale Paragonix Technologies is making the jump to becoming a full transplant logistics provider. |
By Nick Paul Taylor Another day, another artificial intelligence (AI) deal. Tuesday was Sanofi’s turn to partner up, striking a deal worth up to $140 million to work on the discovery of small molecules with its compatriot Aqemia. |
Fierce podcasts Don’t miss an episode |
| In this episode of "The Top Line," we're highlighting the remarkable women featured in our annual Fiercest Women in Life Sciences special report. The list comprises 10 trailblazers changing the leadership landscape in pharma, biotech and medtech. |
|
|---|
|
|
|
Tuesday, December 19, 2023 | 12pm ET / 9am PT Either you want to implement a CLM, or you don’t know how to fix the processes of the one you have in place. Either is a tough place to be in. Join us in this webinar to learn from a CLM solution implementation expert in the highly regulated field of pharmaceuticals. Register now. 
|
|
Whitepaper High performance computing (HPC) combined with artificial intelligence (AI) and machine learning (ML) can speed up research and development processes and dramatically reduce reliance on expensive clinical trials. Download the free solution brief to learn more. Sponsored By: AWS, NVIDIA, and Rescale |
Executive Summary By 2030, the global demand for biologics is projected to grow at a CAGR of 8.7% and the challenges, risks, and costs of bringing large molecule products to market are growing exponentially. Sponsored by: ThermoFisher Scientific |
Whitepaper Learn about the untapped power of AI-driven insights — where innovation meetings precision, effortlessly unlocking benefits for your organization. Sponsored by: Planisware |
Whitepaper Medical devices & consumer wearables are starting to overlap, creating risks & opportunities for traditional medical device companies as well as consumer wearables manufacturers. This paper explores pros and cons from both perspectives. Sponsored by: Blue Matter Consulting |
Whitepaper Improving efficiency and productivity in biologics manufacturing is a longstanding goal within today’s industry, especially now as new and increasingly complex molecules are fundamentally changing technological and operational approaches to drug development. Process intensification can help accelerate this pace of innovation through advanced process development techniques and high productivity manufacturing platforms. Sponsored by: Lonza |
Whitepaper As a leader of technology transfer activities in the industry, Lonza understands the challenges associated with this critical step. Download this White Paper today to learn more. Sponsored by: Lonza |
eBook Emulate in vivo biology with next-generation in vitro technology. Sponsored by: Emulate |
Whitepaper A critical area to consider in selecting a CDMO is their ability to successfully complete technology transfers, which involves an intricate set of activities and disciplines that, if done incorrectly, could result in delays and failures that impact the overall success of your end product. Recognizing what it takes to complete this process effectively and efficiently is crucial to selecting the best partner for your project and product needs. This white paper delivers an analysis of critical success factors for effective technology transfer. Sponsored by: Lonza |
| Edison Ballroom, New York City |
|
|
| |
|
